Semaglutide
- Generic Name
- Semaglutide
- Brand Names
- Ozempic, Rybelsus, Wegovy
- Drug Type
- Small Molecule
- Chemical Formula
- C187H291N45O59
- CAS Number
- 910463-68-2
- Unique Ingredient Identifier
- 53AXN4NNHX
- Background
Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity. Other members of this drug class include Exenatide and Liraglutide. Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017. Th...
- Indication
Semaglutide is indicated to improve glycemic control in adults diagnosed with type 2 diabetes mellitus, and is used as an adjunct to diet and exercise. However, semaglutide is not a suitable first-line drug for diabetes that has not been controlled by diet and exercise. In addition, it has not been studied in patients with pancreatitis. Semaglutide is not in...
- Associated Conditions
- BMI >27 kg/m2, Cardiovascular Events, Obesity, Type 2 Diabetes Mellitus
- Associated Therapies
- Chronic Weight Management therapy
Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function
- First Posted Date
- 2013-12-18
- Last Posted Date
- 2018-04-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 71
- Registration Number
- NCT02014259
- Locations
- 🇭🇺
Novo Nordisk Investigational Site, Budapest, Hungary
Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2013-08-28
- Last Posted Date
- 2019-06-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1231
- Registration Number
- NCT01930188
- Locations
- 🇺🇦
Novo Nordisk Investigational Site, Zaporizhia, Ukraine
Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2013-08-15
- Last Posted Date
- 2021-01-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 632
- Registration Number
- NCT01923181
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, London, United Kingdom
Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2013-06-24
- Last Posted Date
- 2019-06-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 813
- Registration Number
- NCT01885208
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Rotherham, United Kingdom
Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male Subjects
- Conditions
- Interventions
- First Posted Date
- 2013-05-31
- Last Posted Date
- 2014-04-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 170
- Registration Number
- NCT01866748
A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Subcutaneous Injections of Semaglutide Produced by Two Manufacturing Processes
- First Posted Date
- 2013-01-11
- Last Posted Date
- 2014-06-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 28
- Registration Number
- NCT01766245
Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2012-11-02
- Last Posted Date
- 2019-06-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 3297
- Registration Number
- NCT01720446
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Torquay, United Kingdom
Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2012-09-18
- Last Posted Date
- 2019-01-04
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 107
- Registration Number
- NCT01686945
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
Pharmacoscintigraphic Investigation of NN9924 in Healthy Male Subjects
- First Posted Date
- 2012-06-14
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 27
- Registration Number
- NCT01619345
Investigation of Optimal Dosing Conditions for a Long Acting GLP-1 Analogue in Healthy Male Subjects
- First Posted Date
- 2012-04-06
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 161
- Registration Number
- NCT01572753
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.